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In the past 5 y, the 28 d mortality in patients with
sepsis syndrome has decreased somewhat but still
ranges from 30% to 40%; mortality in those patients
with septic shock and multiple organ failure is
higher. This high mortality is observed despite inten-
sive care units that deliver hemodynamic, metabolic,
ventilatory, and renal support. Clearly some patients
survive the ordeal but it remains frustrating not
being able to stop the downhill course leading to
multiple organ failure and death in these patients.
New therapies have been sought and tested, includ-
ing those preventing the biologic activity of two
pro-in¯ammatory cytokines, interleukin-1 (IL-1) and
tumor necrosis factor (TNF). Based on animal
studies, anti-TNF and IL-1 therapy has been used to
``rescue'' the patient who continues to deteriorate
in the face of considerable support efforts. Un-
fortunately, these anticytokine therapies have not
dramatically reduced 28 d mortality in double-blind,
placebo-controlled trials involving nearly 10 000
patients, although there is a consistent but statistic-
ally nonsigni®cant decrease in mortality associated
with anticytokine therapies. On the other hand, the
same anti-TNF and IL-1-based therapies have made
a dramatic improvement in the local in¯ammation
and progression of rheumatoid arthritis. It appears
that systemic in¯ammation of sepsis requires more
than anticytokine monotherapy to signi®cantly
reduce mortality. Key words: interferon-g/interleukin-1/
septic shock/tumor necrosis factor. Journal of Investigative
Dermatology Symposium Proceedings 6:244±250, 2001
C
ytokines are small, nonstructural proteins with
molecular weights ranging from 8 to 40 000 Da.
Originally called lymphokines and monokines to
indicate their cellular sources, it became clear that the
term ``cytokine'' is the best description as nearly all
nucleated cells are capable of synthesis of these proteins and, in
turn, respond to them. There is no amino acid sequence motif or
three-dimensional structure that links cytokines; rather, their
biologic activities allow us to group them into different classes.
For the most part, cytokines are primarily involved in host
responses to disease or infection and any involvement with
homeostatic mechanisms has been less than dramatic.
CYTOKINE RESPONSES TO INFECTION AND
INFLAMMATION
There are presently 18 cytokines with the name ``interleukin''.
Other cytokines have retained their original biologic description
such as ``tumor necrosis factor''. Another way to look at some
cytokines is their role in infection and/or in¯ammation. Hence
some cytokines clearly promote in¯ammation and are called pro-
in¯ammatory cytokines, whereas others suppress the activity of
pro-in¯ammatory cytokines and are called anti-in¯ammatory
cytokines. For example, interleukin (IL)-4, IL-10, and IL-13 are
potent activators of B-lymphocytes; however, IL-4, IL-10, and IL-
13 are also potent anti-in¯ammatory agents. They are anti-
in¯ammatory cytokines by virtue of their ability to suppress
genes for pro-in¯ammatory cytokines such as IL-1, tumor necrosis
factor (TNF), and the chemokines.
IFN-g is another example of the pleiotropic nature of cytokines.
Like IFN-a and IFN-b, IFN-g possesses antiviral activity. IFN-g is
also an activator of the pathway that leads to cytotoxic T cells;
however, IFN-g is considered a pro-in¯ammatory cytokine because
it augments TNF activity and induces nitric oxide (NO).
Therefore, listing cytokines in various categories should be done
with an open mind in that depending upon the biologic process,
any cytokine may function differentially.
THE CONCEPT OF PRO- AND ANTI-INFLAMMATORY
CYTOKINES
The concept that some cytokines function primarily to induce
in¯ammation whereas others suppress in¯ammation is fundamental
to cytokine biology and also to clinical medicine. The concept is
based on the genes coding for the synthesis of small mediator
molecules that are upregulated during in¯ammation. For example,
genes that are pro-in¯ammatory are phospholipase A2 type-II,
cyclooxygenase-2 (COX-2), and inducible NO synthase (iNOS).
These genes code for enzymes increasing the synthesis of platelet
activating factor and leukotrienes, prostanoids, and NO. Another
class of genes that are pro-in¯ammatory are chemokines, small
peptides (8000 Da) that facilitate the passage of leukocytes from the
circulation into the tissues. The prototypic chemokine is
neutrophils chemoattractant IL-8. IL-8 also activates neutrophils
to degranulate and cause tissue damage. IL-1 and TNF are inducers
of endothelial adhesion molecules, which are essential for the
adhesion of leukocytes to the endothelial surface prior to emigra-
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tion into the tissues. Taken together, pro-in¯ammatory cytokine-
mediated in¯ammation is a cascade of gene products usually not
produced in health. What triggers the expression of these genes?
Although in¯ammatory products such as endotoxins do, the
cytokines IL-1 and TNF (and in some cases IFN-g) are particularly
effective in stimulating the expression of these genes. Moreover,
IL-1 and TNF act synergistically in this process. Whether induced
by a infection, trauma, ischemia, immune-activated T cells, or
toxins, IL-1 and TNF initiate the cascade of in¯ammatory
mediators by targeting the endothelium. Figure 1 illustrates the
in¯ammatory cascade triggered by IL-1 and TNF.
On the other hand, anti-in¯ammatory cytokines block this
process or at least suppress the intensity of the cascade. Cytokines
such as IL-4, IL-10, IL-13, and TGF-b suppress the production of
IL-1, TNF, chemokines such as IL-8, and vascular adhesion
molecules. Therefore, a ``balance'' between the effects of pro- and
anti-in¯ammatory cytokines is thought to determine the outcome
of disease, whether short or long-term. In fact, some studies have
data suggesting that susceptibility to disease is genetically deter-
mined by the balance or expression of either pro- or anti-
in¯ammatory cytokines; however, gene linkage studies are often
dif®cult to interpret. Nevertheless, deletion of the IL-10 gene in
mice results in the spontaneous development of a fatal in¯ammatory
bowel disease. Deletion of the TGF-b1 gene also results in a
spontaneous in¯ammatory disease. In mice de®cient in IL-1
receptor antagonist (IL-1Ra), spontaneous disease nearly identical
to rheumatoid arthritis is observed.
IL-1 AND TNF
Synergism of IL-1 and TNF is a commonly reported phenomenon.
Clearly, both cytokines are being produced at sites of local
in¯ammation and hence the net effect should be considered when
making correlations between cytokine levels and severity of disease.
There is also synergism between IL-1 and bradykinin as well as IL-1
or TNF and mesenchymal growth factors. Most relevant to pain is
the increase in PGE2 stimulated by IL-1 or the combination of IL-
1 and TNF. IL-1 also lowers the threshold to pain primarily by
increasing PGE2 synthesis (Schweizer et al, 1988). Table I
summarizes the synergism of IL-1 and TNF.
Humans injected with IL-1 experience fever, headache,
myalgias, and arthralgias, each of which is reduced by coadminis-
tration of cyclooxygenase inhibitors.1 One of the more universal
activities of IL-1 is the induction of gene expression for type-II
phospholipase A2 and COX-2. IL-1 induces transcription of
COX-2 and seems to have little effect on increased production of
COX-1. Moreover, once triggered, COX-2 production is elevated
for several hours and large amounts of PGE2 are produced in cells
stimulated with IL-1. Therefore, it comes as no surprise that many
biologic activities of IL-1 are actually due to increased PGE2
production. There appears to be selectivity in cyclooxygenase
inhibitors in that some nonsteroidal anti-in¯ammatory agents are
better inhibitors of COX-2 rather than COX-1. Similar to COX-2
induction, IL-1 preferentially stimulates new transcripts for the
inducible type-II form of PLA2, which cleaves the fatty acid in the
number 2 position of cell membrane phospholipids. In most cases,
this is arachidonic acid. The release of arachidonic acid is the rate-
limiting step in the synthesis of prostaglandins and leukotrienes.
IL-1 also stimulates increased leukotriene synthesis in many cells.
HOW DOES IL-1 DIFFER FROM TNF IN ACTIVATING
CELLS?
From the above descriptions of IL-1R and IL-1 signal transduction,
many of these pathways are shared with TNF. Although the
receptors for TNF and IL-1 are clearly different, the postreceptor
events are amazingly similar. Thus, the ®nding that IL-1 and TNF
activate the same portfolio of genes is not surprising; however,
given the same cell and given the same array of activated genes,
IL-1 does not result in programmed cell death, whereas TNF does.
This can be seen in TNF responsive ®broblast in which IL-1 and
TNF induce IL-8 but in the presence of actinomycin C or
cycloheximide, TNF induces classical apoptosis but IL-1 does not.
IL-1 will often synergize with TNF for NO induction and under
those conditions, NO mediates cell death. The best example of this
can be found in the insulin-producing b cells in the islets of
Langerhans in the pancreas (Reimers et al, 1994). Unlike IL-1, the
receptors for TNF are homodimers and trimers and hence the
recruitment of kinases is somewhat different; however, the
cytosolic domain of the TNF p55 receptor contains a ``death
domain'' that recruits intracellular molecules involved with initiat-
ing programmed cell death (Boldin et al, 1995). There is no
comparable ``death domain'' in the cytoplasmic domains of either
the IL-1RI or the IL-1R-AcP.
There are two receptors for TNF, the p55 receptor and the p75
receptor (Engelmann et al, 1990). Although TNF binds and triggers
both receptors, the cytosolic domains of these receptors recruit
different proteins that transduce the TNF signal further. In once
case, the p55 receptor cytosolic domain is linked to pathways of cell
death, whereas the p75 is not. Both receptors, however, result in
the translocation of the nuclear factor B (NFkB) to the nucleus,
where it binds to the promoter regions of a variety of genes. These
gene products are often the same as those triggered by IL-1, which
also results in translocation of NFkB to the nucleus. The difference,
however, is that the cytosolic domains of the p55 TNFR are
unique in their ability to activate intracellular signals leading to
programmed cell death (also called apoptosis). The p55 TNFR has
Figure 1. Physiologic events associated with the development of
septic shock.
1Smith JW, Urba WJ, Curti BD, et al: Phase II trial of interleukin-1
alpha in combination with indomethacin in melanoma patients. Proc Am
Soc Clin Oncol 10:293, 1991 (abstr.)
Table I. Synergistic activities of IL-1 and TNF
Hemodynamic shock and lactic acidosis in rabbits
Radioprotection
Generation of Shwartzman reaction
Luteal cell PGF2a synthesis
PGE2 synthesis in ®broblasts
Galactosamine-induced hepatotoxicity
Sickness behavior in mice
Circulating nitric oxide and hypoglycemia in malaria
Nerve growth factor synthesis from ®broblasts
Insulin release and islet beta cell death
Insulin resistance
Loss of lean body mass
IL-8 (and other chemokine) synthesis
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the so-called ``death domain'' and recruits a protein called
MORT-1. Also involved in this process are a family of intracellular
proteins that become activated and are called TRAF for TNF
receptor associated factors. Presently there are six or perhaps eight
TRAF. The p55 cytosolic domains also recruit the family of
intracellular proteins called TNF receptor associated death domains
(TRADD). Overexpression of TRADD results in cell death. It also
leads to activation of NFkB. TRADD also lead to activation of the
caspase family of intracellular cysteine proteases. Although caspase-
1 (also known as the IL-1b converting enzyme, ICE) is important
for processing the precursors for proIL-1b and proIL-18, other
members of this family are also part of the TNF cell death signal
pathway.
One interesting aspect of the biology of TNF in the brain is the
ability of TNF to both protect neurons as well as to initiate their
self destruction. Both pathways involve activation of NFkB
(Hunter et al, 1997). In general, the state of the cell (cell cycle)
may help explain why activation of NFkB can be associated with
both protection of cell death as well as apoptosis. One is reminded
that activation of NFkB leads most often to new protein synthesis;
some proteins from this process are clearly inducing cell prolifer-
ation whereas others induce cell death.
THE PHYSIOLOGIC CATASTROPHE OF SEPTIC SHOCK
AND THE CONCEPT OF RESCUE
The diagnosis of sepsis syndrome or septic shock is based on a
constellation of physiologic, metabolic, and hematologic abnorm-
alities most commonly occurring in patients with a known
infection. In most cases, the patient is already hospitalized with
an antecedent illness or has experienced recent surgery. Many
patients, but not all, are being treated with appropriate antibiotics
for a suspected infection. Approximately 25% of patients with sepsis
syndrome are in hemodynamic shock at the time of presentation
(Sands et al, 1997). Characteristic of septic shock, the hypotension is
unresponsive to rapid ¯uid replacement. In most circumstances,
when blood pressure falls (a 25%±35% reduction), 500 ml of saline
infusion is rapidly administered. If there is no response with an
increase in mean arterial pressure, a diagnosis of refractory
hemodynamic shock is made. In the context of an on-going
infection or suspected new infection, the patient is thought to be in
septic shock.
If the hypotension is not corrected, progressive reduction in
organ perfusion and increasing acidosis leads to tissue hypoxia and
results in organ failure. Although the hypotension is often initially
treated with vasopressor drugs and antibiotics are either changed or
additional antibiotics used, a downhill course can rapidly take place,
resulting in death. In some patients, this rapid downhill course can
be very dramatic and disseminated intravascular coagulation may
develop. This physiologic cascade is illustrated in Fig 1.
There is little question that the major advance in treating patients
with septic shock has been the availability of broad spectrum
antibiotics. In fact, the sooner broad spectrum antibiotics are
administered the lower the mortality rate (Dunn, 1994). The
testing of nonantibiotic-based, novel therapies is based on 50 y of
research on how microorganisms trigger the cascade of events in
septic shock. Although microbial products such as endotoxins are
still targets for therapy, a fundamental concept is that the
constellation of abnormalities in these patients results from the
patient's own response to the infection (or in some cases their
response to massive trauma and blood loss). Initially, activation of
complement was considered causal, particularly the ®fth
component of complement that is a potent neutrophil activator
and produces a capillary leak syndrome. The release of platelet-
activating factor (PAF) was also thought to be responsible,
particularly as PAF is a potent hypotensive agent. Using speci®c
inhibitors of PAF, animals given lethal bacterial toxins survive.
Similar results were obtained when cyclooxygenase inhibitors were
administered to animals challenged with lethal amounts of
endotoxin or bacteria; hence those experiments implicated
cylooxygenase products as a contributing cause to septic shock.
Numerous animal studies also demonstrated the protective effects
of cortiocosteroids, and several large clinical trials using these potent
anti-in¯ammatory agents were undertaken. Clinical trials of PAF
antagonists, cyclooxygenase inhibitors, bradykinin antagonists, and
corticosteroids have each failed to reduce signi®cantly the 28 d
mortality in septic shock patients.
CYTOKINES IN PATHOGENESIS OF SEPSIS AND
SEPTIC SHOCK
The ®eld entered a new era when it was shown that neutralizing
antibodies to the in¯ammatory cytokine TNF prevented death in
mice (Beutler et al 1985), rabbits (Mathison et al 1988), or baboons
(Tracey et al, 1987) following a lethal injection of E. coli or
endotoxin. Previously it had been shown that in the absence of any
infection, high doses of TNF in animals induced circulatory
collapse and organ necrosis (Tracey et al, 1987), which were very
similar to those observed in humans with septic shock (reviewed in
Beutler and Cerami, 1987). Similar results were observed with
high doses of IL-1 in animals (Bertini et al 1988). Injecting a
combination of low doses of IL-1 plus TNF revealed that these
two cytokines acted synergistically in inducing a shock-like
state (Okusawa et al, 1988). Similar to neutralizing TNF
activity, blocking IL-1 receptors were also effective in preventing
death in animal models of lethal bacteremia or endotoxemia
(Ohlsson et al, 1990; Wakabayashi et al, 1991). Because TNF
induces IL-1 and IL-1 induces TNF, synergism between the
two cytokines takes place. For the patient without overt infection,
e.g., multiple trauma, the preclinical data demonstrated that the
systemic injection of either IL-1 or TNF into experimental animals
induced physiologic, hematologic, and pathologic changes that
were nearly identical to those observed during bacteremia or
multiple trauma.
Animal studies were con®rmed when humans were injected
with either IL-1 or TNF. The most impressive physiologic event
following the intravenous injection of either cytokine in humans is
the fall in blood pressure (van der Poll et al 1990). Frank
hypotension has been reported with doses of IL-1 or TNF as low
as 50 ng per kg (Chapman et al, 1987; Smith et al, 1993). The
hypotension is concentration dependent and despite a short plasma
half-life of less than 10 min, the biologic consequences can be
observed for days. In studies in which IL-1 was administered as
adjunct therapy for bone marrow transplant recovery, nearly all
patients required vasopressor therapy (Smith et al, 1992, 1993). In
the case of TNF, an increase in the coagulation parameters and an
early leukopenia occurred (van der Poll et al, 1990, 1991).
THE RATIONALE FOR ANTI-CYTOKINE THERAPY
The biologic basis for the development of a shock-like state
following systemic IL-1 or TNF has been established at the
molecular level. Both cytokines activate the transcription of genes
which increase the production of small, potent mediator molecules.
For example, IL-1 and TNF increase gene expression and synthesis
for phospholipase A2 type II leading to increased PAF synthesis.
Similarly an increase in COX-2 by IL-1 and TNF results in
elevated levels of PGE2 (reviewed in Dinarello, 1996). On a molar
basis, NO is perhaps the most potent vasodilator and is thought to
be primarily responsible for the hypotension and myocardial
suppression in septic shock (Moncada et al 1991). Whereas
constitutive NO production is part of homeostasis, increased
production of NO in in¯ammation takes place when NO is the
product of inducible NO synthase (Fang, 1997). IL-1, TNF, and
IFN-g, particularly the combination of the three, activate gene
expression and synthesis of inducible NO synthase; however, agents
that are competitive inhibitors of arginine will reduce synthesis of
both forms of NO.
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META-ANALYSIS OF SEPTIC SHOCK INTERVENTION
TRIALS
Several double-blinded, placebo-controlled trials were carried out
in order to neutralize TNF activity with either monoclonal anti-
TNF or soluble TNF receptors and to block IL-1 activity with the
IL-1 receptor antagonist (Fisher et al, 1994a, b; Abraham et al, 1995,
1997). With the exception of one trial using the soluble TNFR
p75:Fc (Fisher et al, 1996), there was a small but consistent
improvement in 28 all-cause mortality. The results of these trials in
the overall sepsis syndrome population have been disappointing.
The most recent and largest trial in 105 medical centers recruited
1879 patients with septic shock for randomization to placebo or
neutralizing monoclonal antibodies to TNF. Improved 28 d
survival of 2.5% was observed (40.3% for anti-TNF versus 42.8%
for the placebo) (Abraham et al, 1998). In addition, the results of a
large trial using a construction of two chains of the p55 TNF
extracellular receptor linked to the Fc domain of human IgG has
again revealed no signi®cant reduction in 28 d mortality.
A second Phase III trial in 91 academic centers in North America
and in Europe was initiated intending to randomize 1300 patients
to either placebo or IL-1Ra. The IL-1Ra was administered as an
intravenous bolus injection of 100 mg followed by 3 d of constant
infusion of 2.0 mg per kg per h. The primary endpoint was survival
time in patients with end-organ dysfunction and/or shock at the
time of entry. There were 512 patients who met these entry
criteria. Another 184 were entered into the study but had
secondary endpoints such as shock. A mid-trial analysis was
undertaken after 696 patients had been enrolled. The study was
terminated during an interim analysis because a reduction in overall
28 d mortality would not likely reach statistical signi®cance.
Analysis of the entire 696 patients was made. The 28 d mortality
from all causes in the placebo arm was 36.4% and 33.1% in the
patients receiving IL-1Ra, a 9% reduction in mortality, p = 0.36.
The patient groups were well matched in that 52.9% of the placebo
patients and 50.9% of the IL-1Ra group were in shock at the time
of study entry. There was no excess mortality in patients receiving
IL-1Ra (Opal et al, 1997).
A meta-analysis was performed (Zeni et al, 1997) in order to
examine the outcomes in terms of safety and ef®cacy of the many
trials in septic shock patients. The analysis included 39 trials
conducted over the past 30 y. There were 20 trials of non-
glucocorticoids such as IL-1R antagonist, antibodies to TNF and
bradykinin and PAF antagonists. There were 10 trials for testing of
antiendotoxin antibodies. There were several conclusions to the
analysis: (i) the mortality of the control arm (placebo) for the entire
group of 39 trials was consistently 35%±40%; (ii) high-dose
glucocorticoids showed a harmful effect on survival; (iii) anti-
mediator trials resulted in a small but signi®cant survival bene®t;
and (iv) antiendotoxin trials showed no effect. It is important to
note that with the exception of a single trial (Fisher et al, 1996), the
anticytokine therapy trials did not increase mortality but rather 28 d
mortality was decreased. With anticytokine therapy, the decrease in
mortality was small (2%±5%). This latter result is in contrast to
predictions that blocking the biologic effects of IL-1 or TNF would
reduce host defense and increase mortality. In these highly
vulnerable patients with severe infection, blocking IL-1 activity
or neutralizing TNF had no harmful effect.
OTHER THERAPIES
In mice, treatment with neutralizing antibodies to IFN-g, are
protective against the lethal effect of endotoxemia (Heremans et al,
1990). Similar data have been reported for mice lacking the
receptor for IFN-g (Huang et al, 1993). In mice de®cient in the IL-
1b converting enzyme, there is decreased circulating IFN-g and
these mice are also resistant to endotoxin-mediated death (Kuida et
al, 1995; Li et al, 1995). IFN-g is a potent macrophage activator and
increases the production of and response to TNF; however, in
contrast to a causative role of IFN-g in death in mice, the
administration of IFN-g to several thousand patients with burns,
infections, or cancer is not associated with increased death of
development of shock. In fact, patients with septic shock appear to
bene®t from treatment with IFN-g (Doecke et al, 1997). The
rationale for using IFN-g in patients with septic shock is based on
the observation that some patients exhibit signs of decreased
macrophage and T cell function during sepsis and that IFN-g
restores these immunosuppressed patients. These observations on
IFN-g require a double-blind, placebo-controlled trial using greater
numbers of patients. In a prospective study of 184 patients
undergoing gastrointestinal surgery, depressed monocyte IL-12
production prior to the operation was selectively correlated to the
severity of postoperative sepsis (Hensler et al, 1998).
Other therapeutic approaches in septic patients target the
chemokines and adhesion molecules. Although administration of
large doses of IL-8 to primates does not result in hypotension,
neutralizing antibodies to IL-8 in models of in¯ammation reduce
neutrophil in®ltration in the lung, joint, kidney, skin, and
myocardium (Harada et al, 1996). In particular, anti-IL-8 reduces
neutrophil accumulation into the lung and myocardium following
ischemia-reperfusion injury. If tested in humans, anti-IL-8 therapy
would most likely be used in patients with acute respiratory distress
syndrome (ARDS). IL-8 is increased in bronchoalveolar lavage
specimens from patients with ARDS and, in most patients at risk
for ARDS, elevated bronchoalveolar lavage IL-8 levels have been
predictive of the subsequent development of ARDS (Donnelly et al,
1993). Blocking IL-8 reduces the entrance of neutrophils into
in¯ammatory sites (Harada et al, 1996). Although IL-8 is a sensible
target in septic shock patients, particularly in halting the progress of
ARDS, the production of IL-8 (and other chemokines) is markedly
reduced by the combination of anti-IL-1 and anti-TNF agents. As
shown in Fig 2, blocking the biologic activities of IL-1 and TNF is
Figure 2. Effect of IL-1 and TNF on endo-
thelium. TNF and IL-1 activate endothelial cells
and trigger the cascade of pro-in¯ammatory small
molecule mediators. Increased gene expression for
phospholipase A2 type II, COX-2, and iNOS
results in elevated production of their products,
PAF, PGE2, and NO. Alone or in combination,
these mediators decrease the tone of vascular
smooth muscle and systemic vascular resistance
takes place. IL-1 and TNF also cause increased
capillary leak. The upregulation of endothelial
leukocyte adhesion molecules results in adherence
of circulating neutrophils to the endothelium and
increased production of chemokines such as IL-8
facilitates the emigration of neutrophils into the
tissues. Chemokines also activate degranulation of
neutrophils. Activated neutrophils lead to tissue
destruction, particularly in the lung.
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an upstream strategy for reducing the cascade of secondary
mediators of systemic in¯ammation.
A CLOSER LOOK AT THE PATIENT POPULATION
ENTERING SEPSIS TRIALS
Nearly all of the clinical trials investigating new therapies for sepsis
have used a broad de®nition of the ``sepsis syndrome'', based on
clinical criteria including the presence of tachycardia, hyper- or
hypothermia, and elevated or decreased peripheral white blood cell
counts. These are coupled with the presence of organ system
dysfunction, such as lactic acidosis, disseminated intravascular
coagulation, hypoxemia, hypotension, or decreased urine output.
These entry criteria have permitted patients with a wide range of
underlying illnesses and sources of infection to be treated. There is
little question that these patients form a very heterogeneous
population. For example, patients with clinical evidence of urinary
tract, respiratory, or intra-abdominal infection, with underlying
illnesses as diverse as cancer, autoimmune disorders, chronic renal
failure, and diabetes, were included in the clinical studies with IL-
1Ra or anti-TNF therapies. Infections due to Gram-positive,
Gram-negative, or fungal organisms are included. American and
European studies also re¯ect the dilemma of patient heterogeneity
despite identical entry criteria and drugs (Abraham et al, 1995;
Cohen and Carlet, 1996). The heterogeneity of patients enrolled in
sepsis studies can be contrasted to the de®ned groups used in studies
of IL-1Ra or anti-TNF therapies in rheumatoid arthritis or
in¯ammatory bowel disease. In these latter two diseases, the
underlying mechanism of the disease process is the same for all
patients.
In animal models of infection, cytokine release is dependent on
the source and type of infection. For example, anti-TNF therapies
in murine models appear to work best for bacteremia and have poor
or no ef®cacy in intraperitoneal infections. Yet, only a minority of
patients in the trials examining anti-TNF therapies were bactere-
mic. Furthermore, positive microbial cultures are not reported in
approximately one-third of the patients enrolled into these trials,
despite clinical evidence or suspicion of infection. Therefore, the
actual nature of the infectious process in these patients remains
unclear. In one trial of IL-1Ra, there was a clear survival bene®t
over the placebo in bacteremic patients compared with non-
bacteremic patients (Fisher et al, 1996).
In one study, cytokine levels were used as an entry criterion. In
that trial employing murine anti-TNF Fab2' fragments, a single
circulating IL-6 level greater than 1000 pg per ml was used to
identify a target patient group for this therapy (Reinhart et al,
1996). Although IL-6 levels consistently correlate with disease
severity in most patients with sepsis, patients with infectious and
noninfectious diseases show remarkably variable circulating and
tissue cytokine levels and a single measurement can be misleading.
Because circulating levels of endogenously produced IL-1Ra and
TNF soluble receptors are elevated in sepsis, the net biologically
active IL-1 or TNF remains unclear. IL-6 levels may be a better
marker of the net biologic effect of IL-1 plus TNF. It would appear
more useful to identify for enrollment those patients with increased
generation of biologically active cytokine(s), which is the target of
blocking therapy. Unfortunately, such identi®cation is dif®cult
because TNF and IL-1 are released at their greatest concentrations
at the tissue sites, and rarely do the circulating levels correlate with
the levels of local production. Therefore, clinical criteria will
probably be required to identify patients with increased tissue IL-1
and TNF. These patients appear to be those with a rapidly
occurring onset of organ system dysfunction secondary to infection,
without major underlying and preexistent medical problems. An
example would be the young patient with acute onset of
meningococcemia, in whom circulating and tissue levels of
TNF-a are dramatically elevated. In this setting, the greatest
survival bene®t from anticytokine therapy would be expected
when the agent(s) is given very soon after diagnosis and would be
observed in the period immediately following therapy, as a direct
result of reversal of pro-in¯ammatory cytokine-driven organ
dysfunction.
IS THERE A GENETIC PREDISPOSITION TO
SURVIVING SEPTIC SHOCK?
Targeted deletion of the IL-1Ra gene in mice (also known as IL-
1Ra knockout mice) has resulted in a phenotype highly vulnerable
to endotoxin-induced lethality, whereas mice overexpressing IL-
1Ra appear to be protected against lethal endotoxemia (Hirsch et al,
1996). These latter experiments suggest that endogenous levels of
IL-1Ra may contribute to disease outcome, at least in the case of
septic shock. In addition, in mice de®cient in IL-1Ra, spontaneous
rheumatoid arthritis-like disease develops (Horai et al, 2000). Also,
mice de®cient in IL-1Ra develop a lethal arteritis (Nicklin et al,
2000).
The working hypothesis is that those individuals with the genetic
make-up to produce large amounts of IL-1Ra when septic, are
afforded a greater level of protection than another subject
producing lower levels. The parallel working hypothesis is that
those individuals with the genetic make-up to produce less
bioactive IL-1b when septic, are less likely to die during septic
shock compared with those subjects producing larger amounts of
IL-1b. Although the ultimate proof of these two hypotheses is to
measure the concentrations of IL-1Ra and IL-1b in patients
surviving and compare those levels with those patients dying of
septic shock, such measurements in the context of the acute setting
are affected by nutritional and nongenetic mechanisms present at
the time of infection. Hence, an investigation into the genetic
determinants that may result in high or low IL-1Ra or IL-1b
production should shed some light onto that question.
Messenger RNA does not cause disease. Even if the promoters
for IL-1Ra and the cleavage site for IL-1b are genetically different,
unless these differences result in different levels of the gene product,
polymorphisms are of questionable importance to the outcome of
disease. Nevertheless, there are lessons to be learned from
examination of polymorphisms in cytokine genes. For example,
persons homozygous for the TNFB2 allele of the NcoI site in the
TNF locus are associated with nonsurvival in patients with severe
sepsis (StuÈber et al, 1996). These patients also have elevated TNF-a
levels in the circulation and higher organ failure scores. Although
there is increased mortality with the homozygous TNFB2 allele,
there is no difference between the frequency of this polymorphism
in the general population and the group of patients in the intensive
care unit with a diagnosis of severe sepsis. It appears that if one
develops severe sepsis, inheriting the TNFB2 allele makes one
particularly at risk for death compared with heterozygotes or
patients homozygous for the TNFB1 allele (StuÈber et al, 1996).
Another study (Fang et al, 1999) examined two well-described
genetic polymorphisms in the IL-1 family: the A1-5 allele in intron
2 of the IL-1Ra gene and the Taq1 site in exon 5 of the IL-1b
gene. A comparison of the frequency of these alleles in 93
consecutive patients admitted to the surgical intensive care unit
with 261 local blood donors in apparent health was made. The
results were surprising in that there was a high frequency of the IL-
1RaA2 allele in the cohort with severe sepsis compared with the
healthy cohort (p < 0.01). Although there was no association with
outcome (survival at 28 d), the conclusion of the study suggests that
persons with this allele are more likely to ®nd themselves in a
surgical intensive care unit with severe sepsis that those without the
allele. The internal control for this study was the lack of the Taq1
allele associated with this cohort of 93 patients compared with the
population of 261 persons.
In addition, these studies con®rmed that the TNFB2 allele was
again associated with nonsurvival in this cohort; however, there
was no linkage between these two polymorphisms in the study.
Yet, in eight individuals who were born homozygous for both the
IL-1RaA2 and the TNFB2 alleles, all developed multiple organ
failure with fatal outcome.
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Can we believe that this allele in IL-1Ra makes us more likely to
be a patient with severe sepsis? What is known about this allele and
IL-1Ra production? In one study, the amount of IL-1Ra produced
from patients with insulin-dependent diabetes mellitus was reduced
(Mandrup-Poulsen et al, 1994). In another study, granulocyte-
macrophage colony stimulating factor was used to stimulate IL-1Ra
production and persons with the IL-1RaA2 allele exhibited
increased production compared with those without this allele
(Danis et al, 1995b). In addition, in that study, there was reduced
production of IL-1a in these subjects. Clearly, these results need to
be con®rmed but the concept that a gene polymorphism is
associated with a measurable difference in the amount of the gene
product and an outcome to disease may help resolve the problems
encountered in new therapeutic clinical trials in septic shock
patients. As it now stands, it seems that persons with the IL-1RaA2
allele make more IL-1Ra, which is a risk factor for developing
severe sepsis following a surgical procedure.
Linkage of a particular cytokine gene polymorphism to disease is
not always found in each population studied. For example, a
predisposition to develop severe systemic lupus erythematosus was
linked to the IL-1RaA2 allele in a cohort of persons in the U.K.
(Blakemore et al, 1994). In a cohort living in Australia, this
association was not found (Danis et al, 1995a). Similarly, the
association of the IL-1Ra allele and ulcerative colitis in England
(Mans®eld et al, 1994) was not observed in a cohort of patients
living in Southern Germany (Hacker et al, 1997). Therefore, the
genetic studies in German patients need to be con®rmed in another
population.
NEW APPROACHES TO THERAPY
Although speci®c and successful monotherapy for a particular
disease is a desirable goal in therapeutics, there are increasing
examples where treatment is most effective when two or more
agents are used. The obvious examples are cancer, autoimmune
diseases, and HIV-1 where treatment with a single antitumor drug
or immunosuppressive regimen or antiviral agent has been replaced
with use of several agents, each targeting a somewhat different
mechanism. If more than one agent would bene®t the patient with
septic shock, there are several possible combinations. In sepsis
involving a Gram-negative organism, endotoxin itself acts like a
cytokine in that it activates nearly the same genes as does IL-1 and
TNF-a. A combination of neutralizing antibodies to endotoxin as
well as blocking TNF and/or IL-1 may offer the patient with
Gram-negative septic shock the greatest chance of rescue.
Administration of anti-IL-8 with either anti-TNF or anti-IL-1
may be effective for patients with a high risk of developing ARDS.
The concept of combining more than one anticytokine agent has
sound experimental basis. For example, in animals, a combination
of anti-TNF plus anti-IL-1 treatment has increased survival over
that using either agent as monotherapy.
IS THE FAILURE TO RESCUE PATIENTS WITH ANTI-
TNF OR IL-1 BLOCKADE DUE TO A DELAY IN
INTERVENTION?
Whereas animal studies have provided a compelling argument that
blocking TNF or IL-1 would be a therapeutic success in treating
septic shock, in animals the window of time for reversing the events
of lethal sepsis is rather small. Most studies pretreat animals. Does
that mean that by the time the patient has overt signs of septic
shock that it is too late for rescue with anticytokine therapy? In
most of the anticytokine trials, the time that passes before a patient
actually receives therapy can be 12 h after the randomization
(Abraham et al, 1998). This can be days after the indications of
altered mental status or blood pressure instability are observed. In
one trial using monoclonal anti-TNF-a given within 12 h of the
onset of severe sepsis, there was no change in the sequential samples
of IL-1b, IL-6, or IL-1Ra despite anti-TNF-a intervention and no
effect on physiologic abnormalities (Clark et al, 1998). The
conclusion of the study was that there was inadequate neutraliz-
ation of TNF-a, which was due to either insuf®cient dose or
delayed administration.
What can be done to shorten the time between overt evidence of
a life-threatening process and initiation of anticytokine therapy? In
many patients (75%) with sepsis syndrome, blood pressure and
organ perfusion are unimpaired; however, when septic shock
develops, circulatory collapse within a few hours is thought to
coincide with the onset of a new bacteremia or endotoxemia. In
addition, a ``cytokine storm'' is thought to be responsible for
triggering the shock. It has been the wisdom of anticytokine
therapy that these patients also stand the greatest chance of a
``rescue'' by blocking further cytokine receptor triggering. In other
patients with similarly serious infections, a fall in blood pressure or
the development of organ failure is slower (over days) and cytokine
receptors may have already been engaged before circulatory
collapse reaches the level of entry criteria into a trial. In those
patients, the administration of anticytokine therapy may be too late
to provide a successful rescue.
As noted above, the heterogeneity of the acute infectious and
underlying chronic disease processes in the patients who were
enrolled into sepsis studies may have prevented demonstration of
ef®cacy for anticytokine therapies. Additionally, large numbers of
patients with low risk of mortality were enrolled in these clinical
trials. Such patients often do not have markedly accelerated pro-
in¯ammatory responses amenable to anticytokine therapy, and their
inclusion in the clinical studies may have diluted out any survival
bene®t associated with the use of anticytokine therapy for sepsis.
Therefore, an important advance for future trials would be to
reduce patient heterogeneity. It has been the wisdom that larger
patient cohorts, similar to the 20 000 patients used to evaluate
thrombolytic therapy in acute myocardial infarction, would
compensate for the ``background noise'' of patient heterogeneity
in the sepsis trials; however, increasing the number of patients and
the number of participating hospitals has yielded the same patient
heterogeneity.
Nearly every sepsis trial has uncovered a subgroup de®ned
retrospectively with survival bene®t using the new therapy. When
speci®c subgroups have been retested prospectively in follow-up
larger trials, treating the same subgroup has eluted us in that patient
heterogeneity in the expanded trials dilutes out the ef®cacy beyond
statistical signi®cance. Hence, anticytokine therapy for sepsis still
awaits identi®cation of the patient who can be rescued in a timely
fashion from the downhill cascade caused by in¯ammatory
cytokines.
Supported by NIH Grant AI 15614.
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